Inhaled iloprost for therapy in pulmonary arterial hypertension

References

• Simonneau G, Robbins IM, Beghetti M et al. Updated clinical classification of pulmonary hypertension. J. Am. Coll. Cardiol.54, S43–S54 (2009).
   PubMed Web of Science ®Google Scholar
• Badesch DB, Champion HC, Gomez Sanchez MA et al. Diagnosis and assessment of pulmonary arterial hypertension. J. Am. Coll. Cardiol.54, S55–S66 (2009).
   PubMed Web of Science ®Google Scholar
• Galié N, Hoeper MM, Humbert M et al. Guidelines for diagnosis and treatment of pulmonary hypertension. Eur. Heart J.30, 2493–2537 (2009).
   PubMed Web of Science ®Google Scholar
• Schulz A. Pharmacology of prostanoids. In: Iloprost in Intensive Care Medicine. Ewert R (Ed.). Uni-Med Verlag, Bremen, Germany, 10–30 (2006).
   Google Scholar
• Fisher CA, Kappa JR, Sinha AK et al. Comparison of equimolar concentrations of iloprost, prostacyclin and prostaglandin E1, on human platelet function. J. Lab. Clin. Med.109, 184–190 (1987).
   PubMed Web of Science ®Google Scholar
• Belch JF, Green I, McLaren M et al. The effects of intravenous ZK 36374, a stable prostacyclin analogue, on normal volunteers. Prostaglandins28, 67–71 (1984).
   PubMed Web of Science ®Google Scholar
• Cowley AJ, Heptinstall S, Hampton JR. Effects of prostacyclin and of the stable prostacyclin analogue ZK 36374 on forearm blood flow and blood platelet behaviour in man. Thromb. Haemost.53, 90–94 (1985).
   PubMed Web of Science ®Google Scholar
• Wharton J, Davie N, Upton PD et al. Prostacyclin analogues differentially inhibits growth of distal and proximal human pulmonary smooth muscle cells. Circulation102, 3130–3136 (2000).
   PubMed Web of Science ®Google Scholar
• Clapp LH, Finney P, Turcato S et al. Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery. Am. J. Respir. Cell. Mol. Biol.26, 194–201 (2002).
   PubMed Web of Science ®Google Scholar
• Gomberg-Maitland M, Olschewski H. Prostacyclin therapies for the treatment of pulmonary arterial hypertension. Eur. Respir. J.31, 891–901 (2008).
   PubMed Web of Science ®Google Scholar
• Hsu HH, Rubin LJ. Iloprost inhalation solution for the treatment of pulmonary arterial hypertension. Expert Opin. Pharmacother.6, 1921–1930 (2005).
   PubMed Web of Science ®Google Scholar
• Krause W, Krais T. Pharmacokinetics and pharmacodynamics of radio-labeled iloprost in elderly volunteers. Eur. J. Clin. Pharmacol.32, 597–605 (1987).
   PubMed Web of Science ®Google Scholar
• Schermuly RT, Schulz A, Ghofrani HA et al. Pharmacokinetics and metabolism of infused versus inhaled iloprost in isolated rabbit lungs. J. Pharmacol. Exp. Ther.303, 741–745 (2002).
   PubMed Web of Science ®Google Scholar
• Olschewski H, Rohde B, Behr J et al. Pharmacodynamics and pharmacokinetics of inhaled iloprost, aerosolized by three different devices, in severe pulmonary hypertension. Chest124, 1294–1304 (2003).
   PubMed Web of Science ®Google Scholar
• Pepke-Zaba J, Higenbottam TW, Dinh-Xuan AT et al. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet338, 1173–1174 (1991).
   PubMed Web of Science ®Google Scholar
• Olschewski H, Walmrath D, Schermuly R et al. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann. Intern. Med.124, 820–824 (1996).
   PubMed Web of Science ®Google Scholar
• Hoeper MM, Olschewski H, Ghofrani HA et al. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH study group. J. Am. Coll. Cardiol.35, 176–182 (2000).
   PubMed Web of Science ®Google Scholar
• Ewert R, Schäper C, Halank M et al. Inhalative iloprost – pharmacology and clinical application. Expert Opin. Pharmacother.10, 1–13 (2009).
   PubMed Web of Science ®Google Scholar
• Gessler T, Schmehl T, Hoeper MM et al. Ultrasonic versus jet nebulization of iloprost in severe pulmonary hypertension. Eur. Respir. J.17, 14–19 (2001).
   PubMed Web of Science ®Google Scholar
• Krug S, Sablotzki A, Hammerschmidt S et al. Inhaled iloprost for the control of pulmonary hypertension. Vasc. Health Risk Manag.5, 465–474 (2009).
   PubMedGoogle Scholar
• Tissot C, Beghetti M. Review of inhaled iloprost for the control of pulmonary artery hypertension in children. Vasc. Health Risk Manag.5, 325–331 (2009).
   PubMedGoogle Scholar
• Ghofrani HA, Rose F, Schermuly RT et al. Amplification of the pulmonary vasodilatory response to inhaled iloprost by subthreshold phosphodiesterase types 3 and 4 inhibition in severe pulmonary hypertension. Crit. Care Med.30, 2489–2492 (2002).
   PubMed Web of Science ®Google Scholar
• Wilkens H, Guth A, König J et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation104, 1218–1222 (2001).
   PubMed Web of Science ®Google Scholar
• Ghofrani HA, Wiedemann R, Rose F et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann. Intern. Med.136, 515–522 (2002).
   PubMed Web of Science ®Google Scholar
• Petkov V, Ziesche R, Mosgoeller W et al. Aerosolised iloprost improves pulmonary haemodynamics in patients with primary pulmonary hypertension receiving continuous epoprostenol treatment. Thorax56, 734–736 (2001).
   PubMed Web of Science ®Google Scholar
• Rich S, Brundage BH. High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy. Circulation76, 135–141 (1987).
   PubMed Web of Science ®Google Scholar
• Barst RJ, McGoon M, Torbicki A et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J. Am. Coll. Cardiol.43, 40S–47S (2004).
   PubMed Web of Science ®Google Scholar
• Sitbon O, Humbert M, Jaïs X et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation111, 3105–3111 (2005).
   PubMed Web of Science ®Google Scholar
• Montani D, Savale L, Natali D et al. Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension. Eur. Heart J.31, 1898–1907 (2010).
   PubMed Web of Science ®Google Scholar
• Jing ZC, Jiang X, Han ZY et al. Iloprost for pulmonary vasodilator testing in idiopathic pulmonary arterial hypertension. Eur. Respir. J.33, 1354–1360 (2009).
   PubMed Web of Science ®Google Scholar
• Tonelli AR, Alnuaimat H, Mubarak K. Pulmonary vasodilator testing and use of calcium channel blockers in pulmonary arterial hypertension. Respir. Med.104, 481–496 (2010).
   PubMed Web of Science ®Google Scholar
• Hoeper MM, Schwarze M, Ehlerding S et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N. Engl. J. Med.342, 1866–1870 (2000).
   PubMed Web of Science ®Google Scholar
• Ewert R, Wensel R, Opitz CF. Aerosolized iloprost for primary pulmonary hypertension. N. Engl. J. Med.343, 1421–1422 (2000).
   PubMed Web of Science ®Google Scholar
• Ewert R, Opitz C, Wensel R et al. Iloprost as inhalational and intravenous long-term treatment of patients with primary pulmonary hypertension. Register of the Berlin Study Group for Pulmonary Hypertension. Z. Kardiol.89, 987–999 (2000).
   PubMedGoogle Scholar
• Machherndl S, Kneussl M, Baumgartner H et al. Long-term treatment of pulmonary hypertension with aerosolized iloprost. Eur. Respir. J.17, 8–13 (2001).
   PubMed Web of Science ®Google Scholar
• Olschewski H, Ghofrani HA, Schmehl T et al. Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial. German PPH Study Group. Ann. Intern. Med.132, 435–443 (2000).
   PubMed Web of Science ®Google Scholar
• Olschewski H, Simonneau G, Galiè N et al. Inhaled iloprost for severe pulmonary hypertension. N. Engl. J. Med.347, 322–329 (2002).
   PubMed Web of Science ®Google Scholar
• Hoeper MM, Taha N, Bekjarova A et al. Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids. Eur. Respir. J.22, 330–334 (2003).
   PubMed Web of Science ®Google Scholar
• Seyfarth HJ, Pankau H, Hammerschmidt S et al. Bosentan improves exercise tolerance and Tei index in patients with pulmonary hypertension and prostanoid therapy. Chest28, 709–713 (2005).
   Google Scholar
• Ghofrani HA, Rose F, Schermuly RT et al. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J. Am. Coll. Cardiol.42, 158–164 (2003).
   PubMed Web of Science ®Google Scholar
• Beyer S, Speich R, Fischler M et al. Long-term experience with oral or inhaled vasodilator combination therapy in patients with pulmonary hypertension. Swiss Med. Wkly136, 114–118 (2006).
   PubMed Web of Science ®Google Scholar
• Durongpisitkul K, Jakrapanichakul D, Laohaprasitiporn D et al. Combination therapy of prostacyclin for pulmonary hypertension in congenital heart disease. J. Med. Assoc. Thai.88(Suppl. 8), S60–S65 (2005).
   Google Scholar
• McLaughlin VV, Oudiz RJ, Frost A et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med.174, 1257–1263 (2006).
   PubMed Web of Science ®Google Scholar
• Hoeper MM, Leuchte H, Halank M et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur. Respir. J.28, 691–694 (2006).
   PubMed Web of Science ®Google Scholar
• Olschewski H, Hoeper MM, Behr J et al. Long-term therapy with inhaled iloprost in patients with pulmonary hypertension. Respir. Med.104, 731–740 (2010).
   PubMed Web of Science ®Google Scholar
• Reichenberger F, Mainwood A, Doughty N et al. Effects of nebulised iloprost on pulmonary function and gas exchange in severe pulmonary hypertension. Respir. Med.101, 217–222 (2007).
   PubMed Web of Science ®Google Scholar
• Ivy DD, Doran AK, Smith KJ et al. Short- and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension. J. Am. Coll. Cardiol.51, 161–169 (2008).
   PubMed Web of Science ®Google Scholar
• Opitz CF, Wensel R, Winkler J et al. Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. Eur. Heart J.26, 1895–1902 (2005).
   PubMed Web of Science ®Google Scholar
• McLaughlin VV, Benza RL, Rubin LJ et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension. J. Am. Coll. Cardiol.55, 1915–1922 (2010).
   PubMed Web of Science ®Google Scholar
• Garin MC, Clark L, Chumney EC et al. Cost-utility of treatments for pulmonary arterial hypertension a markov state-transition decision analysis model. Clin. Drug Investig.29, 635–646 (2009).
   PubMed Web of Science ®Google Scholar
• Hoeper MM, Seyfarth HJ, Hoeffken G et al. Experience with inhaled iloprost and bosentan in portopulmonary hypertension. Eur. Respir. J.30, 1096–1102 (2007).
   PubMed Web of Science ®Google Scholar
• Launay D, Hachulla E, Hatron PY et al. Aerosolized iloprost in CREST syndrome related pulmonary hypertension. J. Rheumatol.28, 2252–2256 (2001).
   PubMed Web of Science ®Google Scholar
• Fruhwald FM, Kjellström B, Perthold W et al. Continuous hemodynamic monitoring in pulmonary hypertensive patients treated with inhaled iloprost. Chest124, 351–359 (2003).
   PubMed Web of Science ®Google Scholar
• Melgosa MT, Ricci GL, García-Pagan JC et al. Acute and long-term effects of inhaled iloprost in portopulmonary hypertension. Liver Transpl.16, 348–356 (2010).
   PubMed Web of Science ®Google Scholar
• Reichenberger F, Mainwood A, Morrell NW, Parameshwar J, Pepke-Zaba J. Intravenous epoprostenol versus high dose inhaled iloprost for long-term treatment of pulmonary hypertension. Pulm. Pharmacol. Ther. DOI: 10.1016/j.pupt.2010.06.004 (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Baughman RP, Judson MA, Lower EE et al. Inhaled iloprost for sarcoidosis associated pulmonary hypertension. Sarcoidosis Vasc. Diffuse Lung Dis.26, 110–120 (2009).
   PubMed Web of Science ®Google Scholar